Contrary to what may be believed, rare and genetic diseases concern all of us. They affect 4% to 6% of the population, i.e. 3 million French people and 25 to 30 million Europeans. 80% of these diseases are of genetic origin. For many years, the French Muscular Dystrophy Association (AFM-Téléthon) has been involved in research into rare diseases, and particularly in the development of innovative drugs. The Association also fights to ensure that rare diseases remain a public health priority.
Information and care services
Contrary to what may be believed, rare and genetic diseases concern all of us. They affect 4 to 6% of the population, i.e. 3 million French people and 25 to 30 million Europeans. As the main financier of the Plateforme Maladies Rares, AFM-Téléthon works to maintain recognition of rare diseases as a public health priority, inform patients and the medical establishment and encourage the development of new treatments.
Research into rare diseases funded by AFM-Téléthon
Of the trials supported by AFM-Téléthon, nearly half of them involve non-neuromuscular rare diseases. Each of these trials is strategic because it will stimulate progress in developing treatments for other diseases. With the first successes already achieved.
The National rare diseases plan
Along with the Alliance Maladies Rares (Rare disease alliance - a French group of patient associations), AFM-Téléthon has played a leading role in passing and drafting the first National rare diseases plan launched in 2004, now considered to be a European model.